Ozempic Set to Become More Affordable, Accessible in Canada — Raising Concerns of Drug Abuse

Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to pay patent fee

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper generic copycats

It's easier than ever for Aussies to buy weight loss drugs online. Experts say there should be more checks in place

Fill out a questionnaire, send a few photos, answer a call from a doctor.For some Australians, that's all it takes to get weight loss drugs delivered straight to their door – and it's making experts nervous.A rising number of telehealth companies are offering prescription medications like Wegovy (similar to Ozempic), Saxenda and Mounjaro online without customers ever having to meet a medical professional face-to-face.READ MORE: $120 billion ex…

Canadians could get more affordable version of Ozempic in early 2026. Here’s how

Patients can currently pay $400 a month for popular weight-loss drug

Canadians could get more affordable version of Ozempic in early 2026. Here's how

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as January.

Explained Interview | ‘After obesity, GLP-1 research focused on Alzheimer’s… hypothesis centres on its ability to reduce inflammation in brain…’

Lotte Bjerre Knudsen, Chief Scientific Adviser for Research at Danish pharma giant Novo Nordisk, speaks about GLP-1-based drugs that have changed how the world sees obesity. Research on the hormone and neurotransmitter is on to explore treatment for other conditions, such as Alzheimer's.

Prices down for Wegovy and Zepbound

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven. “The medications should be available, the question is at what price and can people sustain that,” said Matt Maciejewski, a Duke University profes…